Steve Tyrrell is CEO of Laporte and offers more than 25 years of experience leading early stage medical product companies and formal development efforts including SBIR funded grants. Mr. Tyrrell has 32 issued or pending patents, has received both grant and contract support from the NIH, was an invited SBIR reviewer and has taken 3 products through FDA clearance. He has raised capital for 3 companies and sold or licensed multiple technologies.

Steven Dow, DVM, PhD is CSO of Laporte Immunotherapeutics and a Professor in the Department of Clinical Sciences at Colorado State University. His laboratory has brought two products to human trials (melanoma immunotherapeutic, influenza vaccine adjuvant) and one licensed veterinary product (Zelnate, Bayer Animal Health).

Dr. Chow is a Research Scientist in the Laboratory for Immunotherapy, currently investigating respiratory immunotherapeutics for preventing viral and bacterial respiratory tract infections, including coronavirus. Dr. Chow also is a co-inventor on a novel ocular immunotherapy technology. Her work has been critical to the Company’s early successes in developing a new generation of immunotherapies.

Dr. Lappin is a cofounder of Laporte Immunotherapeutics, a Board member and a Professor in the Department of Clinical Sciences at Colorado State University. Dr. Lappin is leveraging industry relationships to generate licensing opportunities for animal health indications of the companies technologies.

Dr. Wotman heads up animal studies involving Ocummune and is an Assistant Professor in Comparative Ophthalmology with CSU. Her areas of clinical interest and research include equine ophthalmology, neoplasia with a focus on equine ocular squamous cell carcinoma (SCC), ocular pain management, corneal disease, glaucoma, and ocular manifestations of systemic disease.